scholarly journals 335. Staphylococcus aureus Bacteremia as a Potential and Severe Complication from Intramuscular COVID-19 Vaccine Injection

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S272-S272
Author(s):  
Miguel Sebastian Pedromingo Kus
Keyword(s):  
Staphylococcus Aureus ◽  
Preventive Measures ◽  
Case Series ◽  
Vaccine Injection ◽  
Staphylococcus Aureus Bacteremia ◽  
Intramuscular Injections ◽  
Vaccine Type ◽  
Rare Side Effect ◽  
Etiological Agents ◽  
The Relationship

Abstract Background Abscess formation and bacteremia following intramuscular injections are rare complications from vaccine injections, and they are most commonly seen in immunocompromised individuals. Staphylococcus aureus is one of the etiological agents that can be found during this complication. Spain started to vaccine its population at the beginning of 2021. We noticed an important increase in Staphylococcus aureus infections and bacteremia during this period of time, leading us to study the relationship with previous vaccination. Methods In this case series we present a cohort of twenty patients with Staphylococcus aureus bacteremia (SAB) during the study period (January 1, 2021 through May 31, 2021), attended in our Institution (Hospital Nuestra Señora de Sonsoles, Ávila, Spain). We tried to establish or at least create the debate of a possible relationship with a previous COVID-19 vaccine. Results From January 1, 2021 through May 31, 2021, 20 SAB were identified in our Institution. 13/20 patients were vaccinated (all of them with the mRNA vaccine type). 5/13 (38%) were male and 8/13 (62%) female. 10 of them (77%) received at least one dose of the vaccine before hospital admission, and 3 of them (23%) after admission. From the 10 previously COVID-19-vaccinated patients treated for SAB (CVPSAB), 4 died - 40% (2 deaths directly related to the SAB). Conclusion Although SAB may be a rare side effect after intramuscular injections or vaccines, it always implies an outstanding risk due to potential complications. Even if our study is not able to directly establish a link between SAB and previous vaccination, it implies a possible association between the vaccine injection and a threating disease (SAB). We should be aware of this probable relationship, so that we can maximize preventive measures. Disclosures All Authors: No reported disclosures

A Retrospective Case Series of Telavancin for the Treatment of Staphylococcus aureus Bacteremia

2018 ◽  
Vol 26 (5) ◽  
pp. 264-269
Author(s):  
Louis D. Saravolatz ◽  
Kerry O. Cleveland ◽  
Khalid Rikabi ◽  
Ali Hassoun ◽  
Joseph Reilly ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Case Series ◽  
Retrospective Case ◽  
Staphylococcus Aureus Bacteremia ◽  
Retrospective Case Series

scholarly journals 2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S772-S772
Author(s):  
Nicholas W Van Hise ◽  
Michael Anderson ◽  
David McKinsey ◽  
Joel McKinsey ◽  
Brian Harting ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Case Series ◽  
Time Frame ◽  
High Morbidity ◽  
Retrospective Case ◽  
Persons Who Inject Drugs ◽  
Staphylococcus Aureus Bacteremia ◽  
Intravenous Antibiotics

Abstract Background Staphylococcus aureus is a significant cause of bacteremia and is associated with high morbidity and mortality rates. In patients with S. aureus bacteremia, studies have proven that intravenous antibiotics are needed for the entire course of therapy. For some groups of patients, specifically in persons who inject drugs (PWID), the long-term use of IV antibiotics is not safe or feasible. In this population, the current options would be obtaining intravenous access daily for antibiotic infusions, oral antibiotics, or being admitted to a facility that can monitor the patient. Data concerning the utilization of dalbavancin for the treatment of S. aureus bacteremia are limited. Methods This was a multicenter, retrospective case series of patients treated with four to six weekly doses of dalbavancin at 5 infusion centers in 3 states under the care of Metro Infectious Disease Consultant (MIDC) physicians between January 1 and December 31, 2018. All patients received intravenous therapy through a peripherally inserted catheter that was removed immediately after the infusion was completed. All patients were evaluated by an MIDC physician at the time of the initial dalbavancin dose, and weekly through their course of therapy. Cure was defined as negative blood cultures and no clinical evidence of persistent or relapsing infection. All patients completed their prescribed dosing and had phone follow-up to assess treatment efficacy at weeks 4, 8, 12, and 24. Results Twenty-one patients were included in the analysis. All patients began therapy for S. aureus bacteremia as inpatients and were transitioned to dalbavancin as outpatients. All patients received dalbavancin 1 g followed by 500 mg doses for at least 3 more weeks with an average of 4 weeks of therapy. Of the 21 patients, 16 were able to be contacted post therapy. Of the 16 patients, 2 patients were readmitted within the 6 month time frame for recurrent bacteremia related to intravenous drug usage. The remaining 14 patients remained disease free at the 6 month interval. No patients experienced a line related issue or C. difficile infection during the course of therapy. Conclusion Use of dalbavancin to treat S. aureus bacteremia infections resulted in clinical cure and markedly decreased healthcare costs. Disclosures All authors: No reported disclosures.

scholarly journals Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series

2020 ◽  
Vol 7 (11) ◽  
Author(s):  
Jaclyn A Cusumano ◽  
Amy C Dupper ◽  
Yesha Malik ◽  
Elizabeth M Gavioli ◽  
Jaspreet Banga ◽  
...  
Keyword(s):  
New York ◽  
Staphylococcus Aureus ◽  
New York City ◽  
Hospital Mortality ◽  
Bacterial Infections ◽  
Case Series ◽  
Mortality Rates ◽  
Day Hospital ◽  
Staphylococcus Aureus Bacteremia ◽  
The Impact

Abstract Background Previous viral pandemics have shown that secondary bacterial infections result in higher morbidity and mortality, with Staphylococcus aureus being the primary causative pathogen. The impact of secondary S. aureus bacteremia on mortality in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unknown. Methods This was a retrospective observational case series of patients with coronavirus disease 2019 (COVID-19) who developed secondary S. aureus bacteremia across 2 New York City hospitals. The primary end point was to describe 14-day and 30-day hospital mortality rates of patients with COVID-19 and S. aureus bacteremia. Secondary end points included predictors of 14-day and 30-day hospital mortality in patients with COVID-19 and S. aureus bacteremia. Results A total of 42 patients hospitalized for COVID-19 with secondary S. aureus bacteremia were identified. Of these patients, 23 (54.8%) and 28 (66.7%) died at 14 days and 30 days, respectively, from their first positive blood culture. Multivariate analysis identified hospital-onset bacteremia (≥4 days from date of admission) and age as significant predictors of 14-day hospital mortality and Pitt bacteremia score as a significant predictor of 30-day hospital mortality (odds ratio [OR], 11.9; 95% CI, 2.03–114.7; P = .01; OR, 1.10; 95% CI, 1.03–1.20; P = .02; and OR, 1.56; 95% CI, 1.19–2.18; P = .003, respectively). Conclusions Bacteremia with S. aureus is associated with high mortality rates in patients hospitalized with COVID-19. Further investigation is warranted to understand the impact of COVID-19 and secondary S. aureus bacteremia.

scholarly journals Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia

2019 ◽  
Vol 63 (5) ◽  
Author(s):  
Matthew Geriak ◽  
Fadi Haddad ◽  
Khulood Rizvi ◽  
Warren Rose ◽  
Ravina Kullar ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Hospital Mortality ◽  
Case Series ◽  
Group Versus ◽  
Standard Of Care ◽  
Interleukin 10 ◽  
Reference Laboratory ◽  
Methicillin Resistant ◽  
Content Type ◽  
Staphylococcus Aureus Bacteremia

ABSTRACT Vancomycin (VAN) and daptomycin (DAP) are approved as a monotherapy for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. A regimen of daptomycin plus ceftaroline (DAP+CPT) has shown promise in published case series of MRSA salvage therapy, but no comparative data exist to compare up-front DAP+CPT head-to-head therapy versus standard monotherapy as an initial treatment. In a pilot study, we evaluated 40 adult patients who were randomized to receive 6 to 8 mg/kg of body weight per day of DAP and 600 mg intravenous (i.v.) CPT every 8 h (q8h) (n = 17) or standard monotherapy (n = 23) with vancomycin (VAN; dosed to achieve serum trough concentrations of 15 to 20 mg/liter; n = 21) or 6 to 8 mg/kg/day DAP (n = 2). Serum drawn on the first day of bacteremia was sent to a reference laboratory post hoc for measurement of interleukin-10 (IL-10) concentrations and correlation to in-hospital mortality. Sources of bacteremia, median Pitt bacteremia scores, Charlson comorbidity indices, and median IL-10 serum concentrations were similar in both groups. Although the study was initially designed to examine bacteremia duration, we observed an unanticipated in-hospital mortality difference of 0% (0/17) for combination therapy and 26% (6/23) for monotherapy (P = 0.029), causing us to halt the study. Among patients with an IL-10 concentration of >5 pg/ml, 0% (0/14) died in the DAP+CPT group versus 26% (5/19) in the monotherapy group (P = 0.057). Here, we share the full results of this preliminary (but aborted) assessment of early DAP+CPT therapy versus standard monotherapy in MRSA bacteremia, hoping to encourage a more definitive clinical trial of its potential benefits against this leading cause of infection-associated mortality. (The clinical study discussed in this paper has been registered at ClinicalTrials.gov under identifier NCT02660346.)

scholarly journals Community-Acquired Methicillin Resistant Staphylococcus aureus Bacteremia: Case Series

2015 ◽  
Vol 13 (1) ◽  
pp. 77-79 ◽  
Author(s):  
E JK Veni ◽  
G Bhat ◽  
SM Shalini ◽  
P Kumar ◽  
M Chakrapani ◽  
...  
Keyword(s):  
Risk Factors ◽  
Staphylococcus Aureus ◽  
Medical Journal ◽  
Soft Tissue ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Case Series ◽  
Soft Tissue Infections ◽  
Methicillin Resistant ◽  
Staphylococcus Aureus Bacteremia ◽  
Invasive Infections

Community-acquired methicillin resistant Staphylococcus aureus (MRSA) usually causes skin and soft tissue infections. However, community-acquired methicillin resistant S.aureus has been identified as a causative agent of many invasive infections like necrotizing fasciitis, pneumonia and bacteremia. Risk factors such as immunodeficiency and skin and soft tissue infections have been identified for acquiring bacteremia. We present four cases of bacteremia caused by community-acquired methicillin resistant S.aureus, risk factors and outcome.Kathmandu University Medical Journal Vol.13(1) 2015; 77-79

scholarly journals Impact of Reduced Vancomycin MIC on Clinical Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia

2013 ◽  
Vol 57 (11) ◽  
pp. 5536-5542 ◽  
Author(s):  
So-Youn Park ◽  
In-Hwan Oh ◽  
Hee-Joo Lee ◽  
Chun-Gyoo Ihm ◽  
Jun Seong Son ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
High Risk ◽  
Clinical Outcomes ◽  
Primary Source ◽  
Methicillin Resistant ◽  
Content Type ◽  
Staphylococcus Aureus Bacteremia ◽  
Significant Difference ◽  
The Impact ◽  
The Relationship

ABSTRACTVancomycin has been a key antibiotic agent for the treatment of methicillin-resistantStaphylococcus aureus(MRSA) infections. However, little is known about the relationship between vancomycin MIC values at the higher end of the susceptibility range and clinical outcomes. The aim of this study was to determine the impact of MRSA bacteremia on clinical outcomes in patients with a vancomycin MIC near the upper limit of the susceptible range. Patients with MRSA bacteremia were divided into a high-vancomycin-MIC group (2 μg/ml) and a low-vancomycin-MIC group (≤1.0 μg/ml). We examined the relationship between MIC, genotype, primary source of bacteremia, and mortality. Ninety-four patients with MRSA bacteremia, including 31 with a high vancomycin MIC and 63 with a low MIC were analyzed. There was no significant difference between the presence ofagrdysfunction and SCCmectype between the two groups. A higher vancomycin MIC was not found to be associated with mortality. In contrast, high-risk bloodstream infection sources (hazard ratio [HR], 4.63; 95% confidence interval [CI] = 1.24 to 17.33) and bacterial eradication after treatment (HR, 0.06; 95% CI = 0.02 to 0.17), irrespective of vancomycin MIC, were predictors of all-cause 30-day mortality. Our study suggests that a high-risk source of bacteremia is likely to be associated with unfavorable clinical outcomes, but a high vancomycin MIC in a susceptible range, as well as genotype characteristics, are not associated with mortality.

Sign in / Sign up

Export Citation Format

Share Document